RxDoctor Payments Data

William Lowery, MD

Gynecologic Oncology · Durham, NCNPI 1063622959

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $56,750 of the $67,466 with a category attached, or 84.1%. AstraZeneca accounts for 91.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $42,338 and has fallen 98.5% since, to $640 in 2025. Among gynecologic oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,466in general payments, 2019–2025

Across 139 payments — averaging $485.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$62K
  • Seagen Inc.$4K
  • Merck$533
  • Eisai Inc.$439
  • Intuitive Surgical$264
  • Johnson & Johnson$157
  • plus $595 from 12 others

What the payments were for

  • Consulting fees$3,5845%
  • Speaking & faculty fees$56,75084%
  • Travel & lodging$3,2585%
  • Food & beverage$3,8746%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,466 in reported general payments places this provider in the 90th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,927
Medicare patients
160
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →